Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Interleukin 2 receptor gamma"'
Autor:
Magdalena Rutkowska-Zapała, Anna Szaflarska, Anna Kluczewska, Julia Ciȩciwa, Jacek Plewka, Anna Michalska, Maciej Siedlar
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
In this study, we report a 4-month-old boy with T−B+NK− severe combined immunodeficiency (SCID) due to a novel mutation in exon 2 of IL2RG, the gene encoding the interleukin (IL) common gamma chain (γc) of the cytokine receptors for IL-2, IL-4,
Externí odkaz:
https://doaj.org/article/2af000e7753d430ead65937845301317
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-8 (2019)
Abstract Background Atypical X-linked severe combined immunodeficiency (X-SCID) is a variant of cellular immunodeficiency due to hypomorphic mutations in the interleukin 2 receptor gamma (IL2RG) gene. Due to a leaky clinical phenotype, diagnosis and
Externí odkaz:
https://doaj.org/article/72288f81d5c04dd8aa2c25b22858adc4
Autor:
Pooja Purswani, Cristina Adelia Meehan, Hye Sun Kuehn, Yenhui Chang, Joseph F. Dasso, Anna K. Meyer, Boglarka Ujhazi, Krisztian Csomos, David Lindsay, Taylor Alberdi, Sonia Joychan, Jessica Trotter, Carla Duff, Maryssa Ellison, Jack Bleesing, Attila Kumanovics, Anne M. Comeau, Jaime E. Hale, Luigi D. Notarangelo, Troy R. Torgersen, Hans D. Ochs, Panida Sriaroon, Benjamin Oshrine, Aleksandra Petrovic, Sergio D. Rosenzweig, Jennifer W. Leiding, Jolan E. Walter
Publikováno v:
Frontiers in Pediatrics, Vol 7 (2019)
In the era of newborn screening (NBS) for severe combined immunodeficiency (SCID) and the possibility of gene therapy (GT), it is important to link SCID phenotype to the underlying genetic disease. In western countries, X-linked interleukin 2 recepto
Externí odkaz:
https://doaj.org/article/7dff6da8b9b04db68c6c1cd6a8c8dac3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrew J. Murphy, Jamie M. Orengo, Thomas Norton, Kirsten Nagashima, Audrey Le Floc’h, Matthew A. Sleeman, Lorah Perlee
Publikováno v:
Transplantation and Cellular Therapy. 27:S250-S251
Autor:
Jennifer W. Leiding, Jolan E. Walter, Sonia Joychan, Aleksandra Petrovic, Anna K. Meyer, Jack J. Bleesing, Yenhui Chang, Benjamin Oshrine, Hye Sun Kuehn, Luigi D. Notarangelo, Attila Kumánovics, Maryssa Ellison, Carla Duff, Krisztian Csomos, Boglarka Ujhazi, Jessica Trotter, Hans D. Ochs, Troy R. Torgersen, Taylor Alberdi, Panida Sriaroon, Pooja Purswani, Anne Marie Comeau, David Lindsay, Jaime E. Hale, Joseph F. Dasso, Cristina Adelia Meehan, Sergio D. Rosenzweig
Publikováno v:
Frontiers in Pediatrics, Vol 7 (2019)
Frontiers in Pediatrics
Frontiers in Pediatrics
In the era of newborn screening (NBS) for severe combined immunodeficiency (SCID) and the possibility of gene therapy (GT), it is important to link SCID phenotype to the underlying genetic disease. In western countries, X-linked interleukin 2 recepto
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-8 (2019)
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-8 (2019)
Background Atypical X-linked severe combined immunodeficiency (X-SCID) is a variant of cellular immunodeficiency due to hypomorphic mutations in the interleukin 2 receptor gamma (IL2RG) gene. Due to a leaky clinical phenotype, diagnosis and appropria
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Petrek Martin, Boyajyan Anna, Zakharyan Roksana, Ghazaryan Hovsep, Melkonyan Ani, Klevcova Petra, Navratilova Zdenka
Publikováno v:
Frontiers in Immunology. 4
Autor:
Jun Wu, Y Yuan, Michele Kirschenbaum, Nymph Chan, George Somlo, Paul Frankel, Masaya Kai, Duc Nguyen, Shiuan Chen, Noriko Kanaya, Shang Wu, Joanne E. Mortimer, H Meng-Yin, Arti Hurria, Courtney Vito, Laura Kruper
Publikováno v:
Cancer Research. 76:P3-03
Background and Purpose: Despite recent progress in our endocrine therapy of hormone receptor positive (HR+) breast cancers, a significant number of patients with primary breast cancer continue to relapse, and those with stage IV disease face a median